Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio Inc.

www.bluebirdbio.com

Latest From bluebird bio Inc.

Bluebird’s Gene Therapy LentiGlobin Coming Into Land In The EU?

Two charities say a positive CHMP opinion has been given to bluebird bio’s transfusion-dependent β-thalassemia gene therapy LentiGlobin at the first meeting of the EMA’s scientific committee at its new home in Amsterdam.

Approvals Blood & Coagulation Disorders

LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting

An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.

Europe Approvals

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.

Regenerative Medicine Financing

Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy

The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.

South Korea Pricing Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • bluebird bio LLC
  • bluebird bio LLC
  • Genetix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Nick Leschly, Pres. & CEO
    Chip Baird, CFO
    Philip Gregory, CSO
    David Davidson, MD, CMO
    Joanne Smith-Farrell, PhD, SVP, Corp. Dev. & Strategy
    Alison Finger, Chief Commercial Officer
  • Contact Info
  • bluebird bio Inc.
    Phone: (339) 499-9300
    60 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register